DK3461905T3 - Hidtil ukendte signalsekvenser til forbedring af proteinekspression og sekretion af rekombinante enzymer og andre proteiner - Google Patents

Hidtil ukendte signalsekvenser til forbedring af proteinekspression og sekretion af rekombinante enzymer og andre proteiner Download PDF

Info

Publication number
DK3461905T3
DK3461905T3 DK18181451.8T DK18181451T DK3461905T3 DK 3461905 T3 DK3461905 T3 DK 3461905T3 DK 18181451 T DK18181451 T DK 18181451T DK 3461905 T3 DK3461905 T3 DK 3461905T3
Authority
DK
Denmark
Prior art keywords
unpermanent
secretion
proteins
protein expression
signal sequences
Prior art date
Application number
DK18181451.8T
Other languages
Danish (da)
English (en)
Inventor
Hung Do
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK3461905T3 publication Critical patent/DK3461905T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18181451.8T 2010-11-22 2011-11-22 Hidtil ukendte signalsekvenser til forbedring af proteinekspression og sekretion af rekombinante enzymer og andre proteiner DK3461905T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41592610P 2010-11-22 2010-11-22
EP11843849.8A EP2643468B1 (en) 2010-11-22 2011-11-22 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins

Publications (1)

Publication Number Publication Date
DK3461905T3 true DK3461905T3 (da) 2020-11-02

Family

ID=46146394

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18181451.8T DK3461905T3 (da) 2010-11-22 2011-11-22 Hidtil ukendte signalsekvenser til forbedring af proteinekspression og sekretion af rekombinante enzymer og andre proteiner
DK11843849.8T DK2643468T3 (en) 2010-11-22 2011-11-22 Hitherto UNKNOWN SIGNAL SEQUENCES TO IMPROVE EXPRESSION AND SECRETARY OF RECOMBINANT ENZYMES AND OTHER PROTEINS

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11843849.8T DK2643468T3 (en) 2010-11-22 2011-11-22 Hitherto UNKNOWN SIGNAL SEQUENCES TO IMPROVE EXPRESSION AND SECRETARY OF RECOMBINANT ENZYMES AND OTHER PROTEINS

Country Status (19)

Country Link
US (1) US9279007B2 (enExample)
EP (2) EP3461905B1 (enExample)
JP (1) JP2014503198A (enExample)
KR (2) KR20190060888A (enExample)
CN (1) CN103328649B (enExample)
BR (1) BR112013012671B1 (enExample)
CA (1) CA2818689C (enExample)
CY (1) CY1121049T1 (enExample)
DK (2) DK3461905T3 (enExample)
ES (2) ES2829199T3 (enExample)
HR (1) HRP20181315T1 (enExample)
HU (1) HUE039070T2 (enExample)
LT (1) LT2643468T (enExample)
PL (1) PL2643468T3 (enExample)
PT (1) PT2643468T (enExample)
RS (1) RS57601B1 (enExample)
SI (1) SI2643468T1 (enExample)
SM (1) SMT201800466T1 (enExample)
WO (1) WO2012071422A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20192243T1 (hr) * 2014-07-03 2020-03-06 F. Hoffmann - La Roche Ag Polipeptidni ekspresijski sustavi
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN111936624A (zh) * 2017-11-30 2020-11-13 阿米库斯治疗学公司 Cdkl5表达变体和cdkl5融合蛋白
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
TW202344691A (zh) 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
JP7577650B2 (ja) 2018-10-10 2024-11-05 アミカス セラピューティックス インコーポレイテッド ジスルフィド結合により安定したポリペプチド組成物及びその使用方法
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
JP2022514863A (ja) * 2018-12-19 2022-02-16 ヴェルサメブ アーゲー タンパク質をコードするrna
BR112021017744A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
US20220193261A1 (en) * 2019-04-30 2022-06-23 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of pompe disease
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021087282A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
CN112342247B (zh) * 2020-11-10 2022-03-11 江苏科技大学 一种提高家蚕细胞表达外源蛋白分泌率的方法
WO2022119890A1 (en) 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
US20250034533A1 (en) 2021-11-12 2025-01-30 Amicus Therapeutics, Inc. Compositions And Methods For Treating Mucopolysaccharidosis IIIA
WO2025264978A2 (en) 2024-06-20 2025-12-26 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a proteins and gene therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031113A1 (en) * 1998-11-24 2000-06-02 Bristol-Myers Squibb Company INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN
EP1689766B1 (en) * 2003-11-06 2012-04-25 Danisco US Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
ATE474917T1 (de) * 2006-04-11 2010-08-15 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide

Also Published As

Publication number Publication date
KR20130121878A (ko) 2013-11-06
CN103328649A (zh) 2013-09-25
ES2829199T3 (es) 2021-05-31
CA2818689A1 (en) 2012-05-31
CN103328649B (zh) 2016-06-22
EP2643468B1 (en) 2018-07-04
EP3461905B1 (en) 2020-08-05
SMT201800466T1 (it) 2018-11-09
KR101984318B1 (ko) 2019-05-31
EP2643468A2 (en) 2013-10-02
LT2643468T (lt) 2018-09-10
US9279007B2 (en) 2016-03-08
RS57601B1 (sr) 2018-11-30
KR20190060888A (ko) 2019-06-03
ES2687415T3 (es) 2018-10-25
JP2014503198A (ja) 2014-02-13
EP3461905A1 (en) 2019-04-03
CY1121049T1 (el) 2019-12-11
WO2012071422A2 (en) 2012-05-31
BR112013012671A2 (pt) 2016-10-11
EP2643468A4 (en) 2014-12-24
US20140045216A1 (en) 2014-02-13
PT2643468T (pt) 2018-10-11
PL2643468T3 (pl) 2018-11-30
HRP20181315T1 (hr) 2018-10-19
SI2643468T1 (sl) 2018-10-30
HUE039070T2 (hu) 2018-12-28
WO2012071422A3 (en) 2012-08-02
CA2818689C (en) 2021-09-21
BR112013012671B1 (pt) 2022-03-03
DK2643468T3 (en) 2018-09-24

Similar Documents

Publication Publication Date Title
PL2643468T3 (pl) Nowe sekwencje sygnałowe do poprawy ekspresji białek i wydzielania ekombinowanych enzymów i innych białek
CY1125705T1 (el) Πρωτεϊνες προσδεσης καλλικρεϊνης πλασματος
DK2547771T3 (da) Fremstilling af proteiner og polypeptider
DK2542590T4 (da) Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
BRPI1015350A2 (pt) anticorpos de anti-ceacam1 e métodos de usar os mesmos
EP2553102A4 (en) HIGH PERFORMANCE EXPRESSION OF RECOMBINANT TOXIN PROTEINS
DK2459715T3 (da) Fremgangsmåde til at oprense rekombinant adamts13 og andre proteiner og sammensætninger deraf
PL2560993T3 (pl) Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
LT3040424T (lt) Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai
DK3604339T3 (da) Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme
EP2426200A4 (en) PROTEIN ELECTRON MEDIATOR
DK2061897T3 (da) Fed-batch-fermenteringsproces med høj celledensitet til fremstilling af rekombinant protein
IL230209B (en) Serpin fusion polypeptides and methods of use thereof
DK2526114T3 (da) Kromatografisk fremgangsmåde til oprensning af FC-indeholdende proteiner
EP2408921A4 (en) MODIFICATION OF CXCR4 USING MODIFIED ZINC FINGER PROTEINS
DK2555629T3 (da) Proteinprodukt og fremgangsmåde til fremstilling af injicérbart proteinprodukt
CO7020851A2 (es) Proteínas y péptidos modificados
DK2598516T3 (da) Fremgangsmåde til proteinoprensning
DK2260873T3 (da) Pcylering af proteiner
IL218474A0 (en) Novel fusion proteins and method of expression thereof
DK2462237T3 (da) Fremgangsmåder til forbedring af rekombinant proteinekspression
DK2547694T5 (da) Hidtil ukendt signalpeptid og anvendelse deraf til fremstilling af rekombinante proteiner
EA201190274A1 (ru) Конструкции casb7439
DK3281636T3 (da) Fremgangsmåde til fremstilling og oprensning af rekombinant lysosomal alfa-mannosidase
IL232759A (en) A method for increased expression of bacterial engineering of recombinant protein and its use